Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction

This study will take place in several periods and phases of treatment: * Observational period of selection of 28 days maximum * Treatment period constituted: * a first phase of treatment with ibrutinib alone (28 days): pre-phase, * a formal protocol phase during which the two study drugs (ibrutinib and daratumumab) will be used together until progression of the disease or intolerance to treatment. * 2-year follow-up period that will begin after protocol processing has been stopped. Selection period (before starting treatment): exams performing to verify patients' eligibility. * Collection of the medical history, * Clinical examination with measurement of height and weight, vital signs (temperature, pulse / heart rate, blood pressure), * Conventional blood tests to check all the functions of the body such as kidney, liver, etc * Viral serologies (Human Immunodeficiency Virus (HIV) and hepatitis B and C) (10 ml). * Blood Pregnancy Test for women who may have children, * Specific blood tests to evaluate the disease and in particular to characterize the cells of LLC (mutational profile, search for chromosomal abnormalities and analysis of residual disease rate to have a reference point before the start of treatment will be made on leukemic cells), * CT scan (thorax, abdomen and pelvis) to accurately search for and evaluate a deep tumor syndrome (lymph nodes, spleen in particular), * Urine examination, * Cardiological examination with an electrocardiogram (ECG).. Treatment period: the treatment period is divided into successive cycles of 28 days. Before starting ibrutinib and before each daratumumab cycle, a complete clinical examination and blood work will be performed. After 12 months of treatment, an evaluation report will be made with a complete clinical examination, a complete blood test, an urinalysis if necessary, a Computed Tomography (CT) scan, a myelogram and if necessary a marrow biopsy. Regularly after this assessment (every 6 months until the end of the study), a report will be made with clinical examination, complete blood test, ECG, CT scan and if necessary, myelogram possibly associated with a marrow biopsy if justified and not previously carried out. After the end of the protocol treatment (progression of the disease, intolerance of the protocol treatment), a last evaluation will be carried out within 30 days after the last taking of the protocol treatment. This evaluation includes a complete clinical examination, biological tests (complete blood test) and a CT scan. Follow-up period the completed treatment you will then be followed in consultation every 6 months for 2 years to evaluate the duration of the response to treatment and thus meet the objectives of the study.